Core Insights - Adia Nutrition Inc. is expanding its clinical research pipeline with plans to launch four to five new studies in 2026, focusing on regenerative therapies using Adia Vita, which is derived from umbilical cord blood [1][4]. Clinical Research Expansion - The planned studies will be conducted at the Adia Med clinic in Winter Park, Florida, and in collaboration with partner clinics across the U.S. [3] - The company is actively seeking Institutional Review Board (IRB) approvals to facilitate multi-site participation for these studies [3][4]. Focus Areas of New Studies - Priority efforts include expanding the existing Autism Spectrum Disorder (ASD) study to include children aged 13, and launching a new study on the effects of Adia Vita in patients with rheumatoid arthritis [8]. - The ongoing ASD study is actively recruiting children aged 3-12 and has received IRB approval [4]. Business Model and Revenue Generation - Adia Nutrition generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments [9]. - The company is also investing in aligned businesses, such as Cement Factory LLC, to enhance its focus on health and wellness [9]. Commitment to Ethical Standards - All research conducted by Adia Med is under strict ethical oversight, informed consent, and regulatory compliance [5]. - The company emphasizes its commitment to advancing regenerative medicine through rigorous and ethical clinical research [4]. Strategic Partnerships - Adia Med is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing its name or integrating its regenerative therapies into their practices [6]. - Collaborations with leading clinics are aimed at accelerating IRB approvals and broadening patient access [4].

Core Viewpoint - Adia Nutrition Inc. has achieved a significant milestone by having its Form 10 registration statement become effective, transitioning the company to full reporting status under SEC regulations, which enhances transparency and prepares for potential uplisting to NASDAQ [1][2][3] Group 1: Company Developments - The Form 10 was filed on December 5, 2025, and became effective automatically 60 days later without further SEC review, marking a transition to full reporting status [2] - CEO Larry Powalisz emphasized that this achievement reflects the company's commitment to governance and investor confidence, while also accelerating preparations for uplisting to NASDAQ [3] - The company is expanding its regenerative medicine platform and clinic network, focusing on advanced treatments in stem cell therapy [3] Group 2: Financial and Operational Highlights - Adia Nutrition generates revenue through service fees, product sales, equity stakes, and insurance billing for healthcare treatments [7] - The company is experiencing significant revenue growth and operational expansion in 2025, positioning itself for continued momentum in personalized healthcare [8] - Adia Nutrition is also investing in aligned businesses, such as Cement Factory LLC, which focuses on health and wellness [7] Group 3: Strategic Partnerships and Initiatives - The company is encouraging clinic owners and healthcare practitioners to license the Adia Med name or integrate its regenerative therapies into their practices [5] - Adia Nutrition is forming strategic partnerships to expand access to advanced stem cell solutions [5] - The company is involved in ongoing clinical studies, including an IRB-approved study on autism spectrum disorder using regenerative stem cell therapy [8]

Core Insights - Adia Nutrition Inc. has appointed Dr. Brian L. Browning as the lead physician for orthopedic treatments at Adia Med, enhancing its leadership in regenerative medicine and orthopedic specialties [1][6][8] Group 1: Company Overview - Adia Nutrition Inc. is based in Winter Park, Florida, and is publicly traded, focusing on advancing healthcare through innovative regenerative medicine solutions [8] - The company specializes in stem cell and regenerative products, including AdiaVita and AdiaLink, and is expanding its offerings to include insurance-billable wound care products [8][9] - Adia Med clinics provide specialized treatments in orthopedic care, pain management, and wound repair, integrating advanced regenerative therapies [8][9] Group 2: Leadership and Expertise - Dr. Browning has extensive experience in orthopedic regenerative treatments and a strong background in family medicine and neuromusculoskeletal medicine [4][5] - He has been involved in training physicians and has a patient-centered approach, which positions Adia Med to offer comprehensive non-surgical regenerative solutions [6][8] Group 3: Services and Treatments - Under Dr. Browning's leadership, Adia Med will offer advanced regenerative treatments such as stem cell therapy, platelet-rich plasma (PRP) therapy, and ultrasound-guided injections for various orthopedic conditions [5][6] - The clinic's services are designed to integrate seamlessly with Adia Med's flagship stem cell therapies, focusing on pain management, sports injuries, and tissue regeneration [5][6] Group 4: Strategic Partnerships and Growth - Adia Nutrition Inc. is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating its regenerative therapies [7] - The company aims to expand access to advanced stem cell solutions as part of its mission to revolutionize healthcare and promote holistic wellness [9]

Core Insights - Adia Nutrition Inc. is set to release a documentary featuring professional wrestler Jeff Sciullo's recovery from a tricep injury, highlighting the effectiveness of its regenerative therapy product, AdiaVita [1][3][5] Company Overview - Adia Nutrition Inc. is based in Winter Park, Florida, and is publicly traded under the ticker OTCQB: ADIA, focusing on advancing healthcare through innovative stem cell and regenerative products [8] - The company operates through its lab division, Adia Labs LLC, and is expanding its services to include insurance-billable wound care products [8] - Adia Med clinics specialize in orthopedic, pain management, and wound repair, offering advanced regenerative treatments such as stem cell therapies and platelet-rich plasma (PRP) [8] Product Details - AdiaVita is a high-potency stem cell product that delivers over 100 million umbilical cord-derived stem cells and more than 3 trillion exosomes per dose, aimed at promoting rapid tissue repair and reducing recovery time for athletes [1][5] - The documentary will showcase the real-world results of the AdiaVita treatment, emphasizing its role in accelerating healing and improving recovery outcomes in sports medicine [5][6] Strategic Partnerships - The documentary is produced in collaboration with The Dr. Asa Network, which is known for its focus on health media and regenerative medicine, enhancing the visibility of Adia's treatments [3][5] - Adia Nutrition Inc. is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating its regenerative therapies into their practices [7] Revenue Generation - The company generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments, indicating a diversified income stream [9] - Adia Nutrition Inc. also invests in aligned businesses, such as Cement Factory LLC, which focuses on health and wellness, further expanding its market presence [9]

Core Insights - Adia Nutrition Inc. is conducting an IRB-approved clinical study for children with Autism Spectrum Disorder (ASD) using umbilical cord blood-derived stem cell and exosome treatments, known as AdiaVita, combined with glutathione to evaluate improvements in ASD symptoms [1][2][3] Study Details - The study is a 24-month randomized, crossover trial targeting approximately 100 children aged 3-12 with confirmed ASD, with primary outcomes focused on changes in Autism Treatment Evaluation Checklist (ATEC) scores [2] - Participants in the active arm will receive three monthly infusions of AdiaVita plus glutathione, while the comparator arm will start with glutathione alone, with crossover options later [2] Previous Results - The trial builds on promising results from a 2025 study involving five children, where families reported significant symptom improvements, including one child with an ATEC score reduction of over 40 points [3] Participation and Costs - Enrollment requires a one-time fee of $12,000, covering all treatments and procedures for both phases of the study, with no monetary incentives offered [4] - The study is designed to ensure that all children receive the full treatment regardless of their initial group, provided they meet safety criteria [4] Global Participation - The trial welcomes children from across the United States and worldwide, reflecting the company's commitment to broad access to regenerative research [5] Company Commitment - The CEO of Adia Nutrition emphasized the company's dedication to transparent and ethical research aimed at supporting children with autism and their families [6] Company Overview - Adia Nutrition Inc. specializes in stem cell and regenerative products, operating through its lab division, Adia Labs LLC, and expanding its services to include insurance-billable wound care products [8] - The company generates revenue through service fees, product sales, and billing insurance for healthcare treatments, while also investing in aligned businesses [9]

Core Viewpoint - Adia Nutrition Inc. has received notification from the SEC that its Form 10 registration statement will automatically become effective on February 3, 2026, marking a significant milestone in its transition to full SEC reporting status [1][2][4]. Group 1: SEC Registration and Reporting - The Form 10 was originally filed on December 5, 2025, and its effectiveness will enhance transparency for investors through regular audited financial disclosures, including annual reports on Form 10-K and quarterly reports on Form 10-Q [2][4]. - The notification from the SEC is seen as a major step forward for Adia Nutrition, as it will provide investors with increased confidence and transparency starting February 3 [3][4]. Group 2: Business Operations and Growth Strategy - Adia Nutrition focuses on delivering innovative healthcare solutions through its divisions, including Adia Med clinics that specialize in advanced stem cell therapies and Adia Labs that provide biologic products to healthcare providers [5][7]. - The company generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments, while also investing in aligned businesses like Cement Factory LLC [8]. Group 3: Future Prospects and Strategic Partnerships - The effectiveness of the Form 10 will trigger standard SEC reporting obligations, aligning Adia with best practices in public company disclosure and positioning it to meet eligibility requirements for potential listing on a national exchange [4]. - The company encourages clinic owners and healthcare practitioners to explore licensing the Adia Med name or integrating its regenerative therapies into their practices, indicating a focus on strategic partnerships to expand access to advanced stem cell solutions [6].

Core Insights - Adia Nutrition Inc. has announced the transition of Emmanuela Derisbrun from subcontractor to employed provider, which is aimed at supporting the increasing patient volume and the launch of an IRB-approved study on regenerative therapies for autism spectrum disorder [1][5] Company Overview - Adia Nutrition Inc. is based in Winter Park, Florida, and is publicly traded under the ticker OTCQB: ADIA. The company focuses on advancing healthcare through innovation, specializing in stem cell and regenerative products [7] - The company operates through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products, and has a network of Adia Med clinics that provide specialized regenerative treatments [7][8] Services and Treatments - Adia Med clinics offer a range of services including orthopedic care, pain management, wound repair, stem cell therapies, platelet-rich plasma (PRP) treatments, therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT) [7] - Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments [8] Professional Development - Emmanuela Derisbrun has extensive experience as a Family Nurse Practitioner and has been involved in administering stem cell treatments and therapeutic plasma exchange while ensuring patient-centered care [3][4] - Her transition to a full-time role is expected to enhance the quality of care and support the ongoing autism IRB study, reflecting the company's commitment to education and safety in investigational therapies [5][6] Strategic Partnerships - The company is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating its regenerative therapies into their practices [6] - Adia Nutrition Inc. also invests in aligned businesses, such as Cement Factory LLC, which focuses on health and wellness, furthering its mission to empower communities with innovative healthcare solutions [8]

Core Insights - Adia Nutrition Inc. has launched a clinical study targeting Autism Spectrum Disorder (ASD), which is now live on ClinicalTrials.gov, representing a significant advancement in the company's research pipeline [1][4]. Group 1: Clinical Study Details - The clinical trial, titled "Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study," aims to enroll approximately 100 children aged 3-12 with confirmed ASD [3]. - The study will evaluate the potential benefits of intravenous glutathione combined with umbilical cord blood-derived stem cells and exosomes (AdiaVita) compared to glutathione alone, focusing on changes in Autism Treatment Evaluation Checklist (ATEC) scores [3]. - The trial includes a 24-month follow-up period, with patient recruitment expected to begin in January 2026 [3]. Group 2: Company Overview - Adia Nutrition Inc. is based in Winter Park, Florida, and specializes in regenerative medicine, particularly through its subsidiary Adia Med [1][6]. - The company generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments [7]. - Adia Nutrition is expanding its offerings to include insurance-billable wound care products and operates Adia Med clinics that specialize in various regenerative treatments [6][7]. Group 3: Strategic Vision - The CEO of Adia Nutrition emphasized the importance of rigorous and transparent research, indicating that this study will serve as a foundational model for additional clinical investigations planned for 2026 [5]. - The company is open to strategic partnerships to expand access to advanced stem cell solutions and encourages clinic owners and healthcare practitioners to integrate Adia's regenerative therapies into their practices [5].

Core Insights - Adia Nutrition Inc. has achieved significant milestones in 2025, including remarkable financial performance and operational expansion, positioning itself for sustained growth and a potential Nasdaq uplisting [1][2] Financial Performance - Preliminary Q3 results indicated a revenue surge of over 200% quarter-over-quarter, with earlier reports showing more than 100% growth and profit margins exceeding 20% [7] - Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments [5] Operational Expansion - The company has tripled its sales force and established four dedicated regional divisions (East Coast, West Coast, Central U.S., and International) to accelerate the distribution of flagship therapies like AdiaVita and AdiaLink [7] - Adia Nutrition is expanding its lab division, Adia Labs LLC, to include insurance-billable wound care products [4] Strategic Partnerships - Adia has become a preferred vendor for the PI Doctors Elite Community, gaining access to over 4,000 personal injury physicians and tapping into the $50 billion personal injury care market [7] - The company is welcoming strategic partnerships to expand access to advanced stem cell solutions [3] Marketing and Visibility - A national marketing campaign has been launched to promote U.S.-based stem cell treatments, targeting orthopedics, pain management, sports injuries, and wound repair [7] - The company is advancing toward greater visibility and accessibility for investors through its Nasdaq aspirations [2] Leadership and Expertise - Key leadership enhancements have been made, including the appointment of Dr. Evan Thomas, MD, PhD, to advance specialized treatment protocols [7] Insurance and Reimbursement - Adia is in advanced negotiations for in-network status with major providers, including Medicare, Medicaid, Humana, Cigna, and Florida Blue, to enable broader reimbursement for AHSCT and stem cell therapies [7] Nasdaq Uplisting Pathway - The company has engaged auditors and counsel and filed SEC Form 10, with expected approval in early 2026, marking a critical step toward full SEC reporting and potential Nasdaq listing [7]

Core Insights - Adia Labs has formed a strategic marketing partnership with BoldMD to enhance the expansion of Axia MD's chiropractor-hosted pop-up longevity clinics across the United States [1][2] Group 1: Partnership and Expansion - The collaboration with BoldMD builds on Adia Labs' existing partnership with Axia MD, which provides physician oversight in all 50 states, creating a compliant platform for scalable growth [2] - The pop-up clinics leverage a network of over 70,000 licensed chiropractors in the U.S., with the chiropractic profession expected to grow approximately 10% over the next decade, more than double the average growth rate for all occupations [3] Group 2: Marketing and Patient Acquisition - BoldMD will implement targeted patient acquisition campaigns, brand development, AI-powered CRM tools, and data-driven marketing strategies to enhance patient retention and optimize marketing efficiency [5] - The partnership aims to support rapid scaling as new clinic locations are launched nationwide, providing advanced regenerative therapies under full physician oversight [3][5] Group 3: Company Overview and Services - Adia Nutrition Inc. specializes in stem cell and regenerative products, with its lab division, Adia Labs LLC, expanding to include insurance-billable wound care products [7] - Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments, with a focus on innovative healthcare solutions [8]